Sign inThe biotech disclosed a non-binding letter of intent to buy a majority stake in an automated-parking wireless charging company for $2.5 million plus a $1.5 million loan.
SEC filing
The company filed a study protocol with an Italian children's hospital for the first clinical test of its drug in this rare genetic disease.
SEC filing
The amendment adds completion details for the Sarborg deal but pushes required financial statements to a later filing.
SEC filing
The company submitted a trial notification and won ethics approval to test its pan-RAS(ON) ADC AN4035 in Australia, with dosing expected in the second half of 2026.
SEC filing
The two CNS-focused drugmakers plan to combine into a single company with about $2.2 billion in pro forma net revenue, targeting a close in the fourth quarter of 2026.
SEC filing
The companies outlined a stock-for-stock combination creating a $2.2 billion CNS company with 11 medicines and targeted cost synergies of at least $125 million.
SEC filing
MAIA-ovarian interim data still expected by Q1 2027 as partnered programs advance and net loss narrows to $7.0 million.
SEC filing
Tonix Pharmaceuticals reported that a Type C meeting with the FDA yielded agreement on the design of an adaptive Phase 2 field study for its monoclonal antibody TNX-4800, with a planned start in early 2027.
SEC filing
The company estimates roughly $12 million in annual cash interest savings from the amendment, which does not change the 2032 maturity date.
SEC filing
The filing details the July 31, 2026 stock sale to longtime investor OPKO as Cocrystal's norovirus drug CDI-988 nears Phase 1b topline data.
SEC filing
The offering priced shares and warrants at $0.75 apiece, with proceeds earmarked for Annamycin development and working capital.
SEC filing
The efficacy supplement for the radioligand therapy Pluvicto was approved with a status date of July 31, 2026.
Drugs@FDA
The company also disclosed a partial response in a RAD 204 trial patient and a quarterly cash outflow that leaves under one quarter of runway before recent raises.
SEC filing
Interim blinded data from 62 evaluable subjects show remission rates holding steady even as more venetoclax-failure patients enter the pivotal trial.
SEC filing
The European Commission cleared AstraZeneca and Daiichi Sankyo's Datroway for patients with metastatic triple-negative breast cancer who cannot receive immunotherapy, citing a survival benefit.
SEC filing
AbbVie announced a definitive deal for Apogee's immunology pipeline, adjusted its full-year adjusted EPS range, and reported a string of regulatory approvals across its portfolio.
SEC filing
Tenax says topline Phase 3 LEVEL results are expected in August 2026 and will be presented at the ESC Congress, while enrollment continues in a second pivotal trial, LEVEL-2.
SEC filing
The July 30, 2026 agreement ends Kyorin's license and hands aTyr full rights to develop and commercialize efzofitimod worldwide.
SEC filing
The Melbourne, Florida biotechnology company reported $350,000 sold so far from one investor, with a first sale date of July 17, 2026.
SEC filing
The company disclosed in a July 31, 2026 filing that Professor Peled stepped down for personal reasons, effective August 1, 2026.
SEC filing
The Zurich-based biopharmaceutical company will sell shares and warrants to fund its lead type 1 diabetes program after a recent FDA Pre-IND meeting.
SEC filing
Werewolf said it expects to report strategic-review and clinical trial updates in the second half of 2026 after closing its JZP898 sale to Jazz and repaying its K2 loan.
SEC filing
The moves are tied to stockholder approval of proposals needed to complete Quince's acquisition of Orphai Therapeutics and related financing.
SEC filing
The company set terms for a previously announced offering, with underwriters exercising their warrant option in full, expected to close July 31, 2026.
SEC filing (3)
The neuroscience drug development veteran joins as Vistagen advances its pherine pipeline, including Phase 3 fasedienol for social anxiety disorder.
SEC filing
The company is offering 12 million shares as its lead sleep apnea drug candidate awaits FDA decision by February 28, 2027.
SEC filing
The filing shows Armistice Capital already holds 31.18% of VivoSim before the offering, with warrant terms tied to a stockholder-approval trigger.
SEC filing
The company said mRNA-1403 did not clear a Phase 3 interim efficacy threshold as it awaits an August 5 FDA decision on flu vaccine mFLUSIVA.
SEC filing
Disc Medicine completed a Type A meeting with the FDA and said its ongoing Phase 3 APOLLO study could support a CRL response for bitopertin in EPP, with topline data expected in the fourth quarter of 2026.
SEC filing
Agios said its mitapivat sNDA in sickle cell disease has a PDUFA date of November 1, 2026, while it licensed cevidoplenib and dropped tebapivat from two programs.
SEC filing
The company said it opened a new FDA IND for early Alzheimer's disease and is prioritizing blarcamesine programs in Alzheimer's, Rett syndrome and Fragile X syndrome.
SEC filing
The board approved an amended inducement plan on July 28, 2026, raising total reserved shares to 3,350,000 for awards to new hires.
SEC filing
Company says enrollment is advancing in its ASCEND trial and a China combination study, with cash extended into second half of 2028 after a $143.7 million offering.
SEC filing
Second-quarter revenue rose 22% to $77.5 million as Vericel filed for U.K. authorization of MACI and its board approved the company's first share repurchase program.
SEC filing